Mild side effects can occur with Ingrezza use. This list doesn’t include all possible mild side effects of the drug. For more information, you can refer to Ingrezza’s prescribing information.

Chief executive Kevin Gorman didn’t disclose Ingrezza’s price today, but this will be revealed ahead of its launch on 1 May. There are more major milestones ahead for the San Diego-based ...

Management proffered guidance for Ingrezza sales of $2.5 billion to $2.6 billion this year, which wouldn't represent hot growth over the 2024 tally of $2.3 billion. Both Guggenheim's Yatin Suneja ...

That wasn't shared. But here's what I found in a key study: Among 202 study participants with TD, only 24% reported having minimal or no symptoms of TD after six weeks of treatment with Ingrezza.

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...

The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate.

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated ...

Its flagship product, Ingrezza (valbenazine), is for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. The company’s Crinecerfont recently obtained ...

Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives. Neurocrine ...